The recent discovery that the small immunomodulatory drug thalidomide induces ubiquitylation and degradation of SALL4 by the CRL4CRBN E3 ubiquitin ligase [50] has demonstrated that this transcription factor can be targeted for cancer therapy [48, 50]. This evidence concerns the gene SALL4 and cancer.